Endocrinology and metabolism (Seoul, Korea)最新文献

{"title":"TAZ WW Domain-Mediated Regulation of Gluconeogenesis and Tumorigenesis in Hepatocellular Carcinoma through Interaction with the Glucocorticoid Receptor.","authors":"Hongxiang Huang, Jinhong Chen, Xingyu Tao, Peiyuan Zhong, Yanqiu Meng, Sujuan Peng, Wanying Luo, Zhiyong He, Shuai Luo, Xie Zhu, Zhihui Lu, Li Chen, Yangyang Liu","doi":"10.3803/EnM.2025.2471","DOIUrl":"10.3803/EnM.2025.2471","url":null,"abstract":"<p><strong>Backgruound: </strong>Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality, characterized by poor prognosis due to its high proliferative and invasive potential. Tumor metabolic reprogramming, particularly involving glucose metabolism, is essential for tumor survival. This study investigates the role of the Hippo pathway effector transcriptional co-activator with PDZ-binding motif (TAZ) in regulating gluconeogenesis and promoting tumorigenesis in HCC.</p><p><strong>Methods: </strong>TAZ expression in HCC was analyzed using The Cancer Genome Atlas data and validated in clinical samples and cell lines. TAZ was overexpressed or silenced in HCC cell lines to evaluate its effects on cell proliferation, apoptosis, migration, and invasion. The expression and prognostic relevance of the gluconeogenesis-related genes phosphoenolpyruvate carboxykinase 1 (PCK1) and glucose-6-phosphatase (G6PC) were examined, along with their correlation with TAZ expression. Tumor growth was assessed in nude mice. Interactions between TAZ and the glucocorticoid receptor (GR) were investigated using co-immunoprecipitation, immunofluorescence, and chromatin immunoprecipitation assays.</p><p><strong>Results: </strong>TAZ was significantly upregulated in HCC tissues and cell lines. TAZ overexpression enhanced proliferation, reduced apoptosis, and promoted migration and invasion. In contrast, PCK1 and G6PC were downregulated in HCC and showed a negative correlation with TAZ expression.</p><p><strong>Conclusion: </strong>TAZ modulates gluconeogenesis and accelerates tumor growth, whereas its knockdown attenuates tumor progression. TAZ interacts with GR, suppressing its transcriptional activity on gluconeogenic gene promoters.</p>","PeriodicalId":520607,"journal":{"name":"Endocrinology and metabolism (Seoul, Korea)","volume":" ","pages":"267-287"},"PeriodicalIF":4.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13172596/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146160080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond a Universal Threshold: Reconsidering the Clinical Meaning of Vitamin D Insufficiency.","authors":"Kyoung Jin Kim","doi":"10.3803/EnM.2026.3060","DOIUrl":"10.3803/EnM.2026.3060","url":null,"abstract":"","PeriodicalId":520607,"journal":{"name":"Endocrinology and metabolism (Seoul, Korea)","volume":"41 2","pages":"231-234"},"PeriodicalIF":4.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13172637/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147877118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lack of Association between Vitamin D Insufficiency and Cardiovascular or Fracture Risk: A UK Biobank Study.","authors":"Yongin Cho, Jong Hyun Jhee, Jong Ho Jhee, Hye-Sun Park","doi":"10.3803/EnM.2025.2482","DOIUrl":"10.3803/EnM.2025.2482","url":null,"abstract":"<p><strong>Backgruound: </strong>Vitamin D deficiency has been linked to increased risks of fractures and cardiovascular (CV) events, but the clinical relevance of the 'insufficiency' range remains unclear. We investigated CV and fracture risks across vitamin D levels, with a focus on the insufficiency range.</p><p><strong>Methods: </strong>Using UK Biobank data, we analyzed 375,044 participants aged 40 to 69 years. Vitamin D status was categorized as deficient (<50 nmol/L), insufficient (≥50 to <75 nmol/L), or sufficient (≥75 nmol/L). Outcomes included three-point major adverse cardiovascular events (3P-MACE; myocardial infarction, stroke, and CV mortality) and major osteoporotic fractures, assessed via hospital records, registries, and death certificates.</p><p><strong>Results: </strong>The vitamin D-deficient group had an increased risk of CV events (adjusted hazard ratio [aHR], 1.17; 95% confidence interval [CI], 1.11 to 1.24) and fractures (aHR, 1.09; 95% CI, 1.01 to 1.18) compared to the vitamin D-sufficient group. Within the deficient group, the severely deficient group (<30 nmol/L) exhibited a markedly higher risk (aHR, 1.29; 95% CI, 1.21 to 1.37 for 3PMACE; and aHR, 1.20; 95% CI, 1.10 to 1.32 for fractures). In contrast, the vitamin D-insufficient group (50 to 75 nmol/L) showed no significant increase in the risk of either outcome, with no clear benefit or harm observed. Spline curve analysis revealed a negative correlation between vitamin D levels and risk, which was observed only within the deficient range and not within the insufficient range.</p><p><strong>Conclusion: </strong>Vitamin D deficiency is strongly associated with increased CV disease and fracture risks, whereas the insufficiency range shows no significant risk or benefit, raising questions about its clinical relevance.</p>","PeriodicalId":520607,"journal":{"name":"Endocrinology and metabolism (Seoul, Korea)","volume":" ","pages":"308-318"},"PeriodicalIF":4.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13172631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145294988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond Weight Loss: Skeletal Considerations in Obesity Treatment.","authors":"Myung Jin Kim, Yun Kyung Cho","doi":"10.3803/EnM.2026.2986","DOIUrl":"10.3803/EnM.2026.2986","url":null,"abstract":"<p><p>The rapid evolution of obesity therapeutics, led by glucagon-like peptide-1 receptor agonists (GLP-1RAs) and metabolic surgery, has achieved unprecedented weight loss. However, the skeletal consequences of such substantial weight reduction are of increasing clinical concern. This review explores the relationship between obesity, weight-loss modalities, and bone health. While obesity was historically viewed as bone-protective due to mechanical loading, recent evidence highlights qualitative bone deterioration and sitespecific fracture risks. Intentional weight loss through caloric restriction or bariatric surgery consistently accelerates bone turnover and reduces bone mineral density (BMD), with surgical interventions showing the most significant impact. Emerging data on GLP-1RAs suggest modest BMD declines, largely proportional to weight loss and likely driven by mechanical unloading. Conversely, preclinical studies indicate that GLP-1 signaling may exert direct osteoanabolic and anti-resorptive effects. To preserve skeletal integrity, obesity management must shift toward a holistic body composition framework. Integrating structured resistance exercise, optimizing nutrition (calcium, vitamin D, and protein), and implementing skeletal monitoring in high-risk individuals are essential. Future obesity care should prioritize the maintenance of bone quality and lean mass alongside fat reduction to ensure long-term skeletal resilience and prevent fragility fractures.</p>","PeriodicalId":520607,"journal":{"name":"Endocrinology and metabolism (Seoul, Korea)","volume":" ","pages":"210-221"},"PeriodicalIF":4.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13172636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147641275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete Blood Count Parameters and Bone Health: Clinical and Experimental Evidence (Endocrinol Metab 2025;40:811-20, Jeonghoon Ha et al.).","authors":"Jeonghoon Ha, Joy Y Wu","doi":"10.3803/EnM.2026.3026","DOIUrl":"10.3803/EnM.2026.3026","url":null,"abstract":"","PeriodicalId":520607,"journal":{"name":"Endocrinology and metabolism (Seoul, Korea)","volume":"41 2","pages":"335-336"},"PeriodicalIF":4.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13172630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147877116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Fatty Liver Index on Cardiovascular Disease and Mortality across Alcohol Consumption Levels in Young Adults.","authors":"Byung-Hun Han, Joonyub Lee, Hun-Sung Kim, Jae-Hyoung Cho, Kyungdo Han, Seung-Hwan Lee","doi":"10.3803/EnM.2025.2710","DOIUrl":"10.3803/EnM.2025.2710","url":null,"abstract":"<p><strong>Background: </strong>The fatty liver index (FLI) is widely used as a surrogate marker for metabolic dysfunction–associated steatotic liver disease, but association with cardiovascular disease and mortality among individuals who consume alcohol remains uncertain. We aimed to investigate the association between FLI and the risk of cardiovascular disease (CVD) and mortality in young adults by alcohol consumption status.</p><p><strong>Methods: </strong>Using the Korean National Health Information Database, we identified 6,487,686 individuals aged 20-39 years who underwent health examinations between 2009 and 2012. FLI was calculated using body mass index, waist circumference, triglycerides, and γ-glutamyl transferase, and categorized as <30, 30-59, or ≥60. Alcohol consumption was classified as non-drinking, mild, moderate, or heavy using sex-specific thresholds. Risks of CVD-including myocardial infarction (MI) and stroke-and all-cause mortality were evaluated using multivariable Cox proportional hazards models.</p><p><strong>Results: </strong>During a mean follow-up of 13.3 years, 49,399 MI, 29,842 stroke, and 53,330 deaths were identified. The risk of CVD and mortality increased stepwise across higher FLI categories in all alcohol consumption groups. Compared with participants with FLI <30, the adjusted hazard ratios (95% confidence intervals [CIs]) for composite outcome among those with FLI ≥60 were 1.72 (95% CI, 1.67 to 1.77) in non-drinkers, 1.41 (95% CI, 1.38 to 1.43) in mild drinkers, 1.19 (95% CI, 1.15 to 1.24) in moderate drinkers, and 1.20 (95% CI, 1.12 to 1.30) in heavy drinkers. The association was strongest among non-drinkers (P for interaction <0.0001).</p><p><strong>Conclusion: </strong>Higher FLI was associated with an increased risk of CVD and mortality in young adults across alcohol consumption levels, with the strongest association observed among non-drinkers.</p>","PeriodicalId":520607,"journal":{"name":"Endocrinology and metabolism (Seoul, Korea)","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147577480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting the Role of Vitamin D in Fracture Prevention in the Era of Mega-Trials.","authors":"Sung Hye Kong","doi":"10.3803/EnM.2029.2938","DOIUrl":"https://doi.org/10.3803/EnM.2029.2938","url":null,"abstract":"<p><p>For decades, vitamin D has been a cornerstone of preventive medicine. However, recent large-scale randomized controlled trials have failed to replicate the broad benefits previously observed in epidemiological studies, particularly with respect to fracture and fall prevention in vitamin D-replete populations. Moreover, growing evidence suggesting an increased fall risk associated with highdose bolus administration has necessitated a re-evaluation of safety assumptions. This review synthesizes these discordant findings to propose a framework grounded in precision medicine. We explore the 'divergent threshold' hypothesis, whereby a serum 25-hydroxyvitamin D level of 20 to 30 ng/mL may be sufficient for skeletal health, whereas a higher threshold of 40 to 50 ng/mL appears necessary to achieve metabolic benefits, such as diabetes prevention in non-obese individuals. Ultimately, we advocate a shift away from a 'one-size-fits-all' paradigm toward targeted strategies that maximize efficacy while minimizing the risks associated with excess supplementation.</p>","PeriodicalId":520607,"journal":{"name":"Endocrinology and metabolism (Seoul, Korea)","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147350109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GYG1 as a Dual Biomarker of Glucagon-Like Peptide-1 Receptor Agonist Weight-Loss Response: Findings from an Integrative Multi-Omics Substudy of a Phase II Trial.","authors":"Lijun Li, Mengyu Hou, Qiannan Gao, Liyuan Zhao, Ruihua Dong","doi":"10.3803/EnM.2025.2641","DOIUrl":"10.3803/EnM.2025.2641","url":null,"abstract":"<p><strong>Background: </strong>The global obesity crisis requires precision biomarkers to overcome treatment resistance. We investigated circulating multi-omics signatures for predicting and monitoring glucagon-like peptide-1 receptor agonist (GLP-1RA) (GZR18) response, addressing gaps in personalized obesity therapy.</p><p><strong>Methods: </strong>We conducted longitudinal multi-omics profiling (proteomics, metabolomics, and lipidomics) of 221 plasma samples from 25 participants (n=25) treated with GZR18 at nine time points over 30 weeks (four samples could not be tested due to hemolysis). High-resolution mass spectrometry quantified molecular features alongside clinical body mass index (BMI) trajectories. Theil-Sen regression modeled baseline predictors (BMI slope Z), while linear regression analysis identified longitudinal biomarkers (%BMI change). Significant candidates (P<0.05) underwent gene set enrichment analysis (GSEA; Kyoto Encyclopedia of Genes and Genomes [KEGG] pathways) and STRING network integration, with dual-response biomarkers validated through correlation and trajectory analyses.</p><p><strong>Results: </strong>GZR18-treated obese patients exhibited a dose-dependent reduction in BMI, with 48 mg biweekly producing the steepest declines (Z<-0.4 vs. placebo: Z=-0.22, P<0.001). We identified glycogenin 1 (GYG1) as a dual-function biomarker (coefficient=2.0 for prediction, P<0.05 for monitoring) and as a central network hub. Lipidomic (phosphatidylinositol 18:2-18:2) and metabolomic (oxoglutaric acid) markers predicted baseline response, while proteomic (insulin like growth factor binding protein 2 [IGFBP2]) and lipidomic (phosphatidylcholine 18:0-20:3) profiles tracked longitudinal efficacy (P<0.05). Adipocytokine signaling governed the initial response (normalized enrichment score >1.8), while starch/sucrose metabolism modulated ongoing efficacy through integrated molecular networks.</p><p><strong>Conclusion: </strong>This study establishes GYG1 as a clinically actionable, dual-function biomarker for GLP-1RA therapy in obesity, linking baseline prediction and real-time monitoring of treatment response through integrated multi-omics profiling. Our findings highlight convergent metabolic pathways driving therapeutic efficacy and provide a precision-medicine framework for optimizing obesity pharmacotherapy through blood-based molecular signatures.</p>","PeriodicalId":520607,"journal":{"name":"Endocrinology and metabolism (Seoul, Korea)","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146115454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consensus on the Diagnosis of Cushing's Disease: A Collaborative Statement from the Korean Endocrine Society and Japan Endocrine Society.","authors":"Jeongmin Lee, Hidenori Fukuoka, Seung Shin Park, A Ram Hong, Jung Hee Kim, Sang Ouk Chin, Han-Sang Baek, Dong-Jun Lim, Kazunori Kageyama, Mitsuru Nishiyama, Shigeyuki Tahara, Kenichi Oyama, Akira Sugawara, Miho Yamashita, Naoko Inoshita, Hiroshi Arima, Byung-Joon Kim, Yoon-Sok Chung, Soon Jib Yoo, Michio Otsuki, Mi-Kyung Kim","doi":"10.3803/EnM.2025.2707","DOIUrl":"10.3803/EnM.2025.2707","url":null,"abstract":"<p><p>Cushing's disease (CD) is a rare but serious endocrine disorder caused by excessive cortisol secretion due to adrenocorticotropic hormone-secreting pituitary tumors. Despite recent developments in diagnostic criteria and treatment options, CD remains associated with substantial comorbidities and mortality. Early and accurate diagnosis is thus essential. Both the Korean Endocrine Society (KES) and Japan Endocrine Society (JES) guidelines are intended to standardize diagnostic approaches to CD, and they share common principles; however, notable differences exist, particularly in biochemical testing thresholds and imaging recommendations. This consensus statement integrates clinical evidence and expert practice from both the KES and JES to establish harmonized recommendations for biochemical evaluation, imaging, and differential testing. This unified framework is intended to enhance diagnostic precision and improve clinical outcomes across East Asian populations.</p>","PeriodicalId":520607,"journal":{"name":"Endocrinology and metabolism (Seoul, Korea)","volume":" ","pages":"1-13"},"PeriodicalIF":4.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12963774/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Knowledge on Atypical Parathyroid Tumors and Emerging Strategies for Risk Stratification.","authors":"Hye-Sun Park, Milim Kim, Jong Ju Jeong, Namki Hong, Yumie Rhee","doi":"10.3803/EnM.2025.2846","DOIUrl":"10.3803/EnM.2025.2846","url":null,"abstract":"<p><p>Atypical parathyroid tumors (APTs) are an uncommon subset of parathyroid neoplasms that carry substantial clinical relevance because of their histological and clinical resemblance to parathyroid cancer. Despite this importance, the diagnosis of APTs remains persistently challenging, even for experienced pathologists. Their histopathological features overlap extensively with those of parathyroid cancer, and at present, no specific immunohistochemical markers are available that can reliably distinguish between these entities. Moreover, the clinical manifestations of APTs are indistinguishable from those of parathyroid adenomas or true parathyroid cancer. A major concern is the uncertain malignant potential of APTs, which contributes to difficulties in prognostic prediction and the absence of standardized surveillance guidelines. Although most published studies suggest a benign clinical course for the majority of APTs, these conclusions are frequently limited by relatively short follow-up durations. This limitation is underscored by several case reports describing recurrence or metastatic disease in patients initially diagnosed with APTs, subsequently prompting reclassification as parathyroid cancer. Recent advances in molecular technologies, particularly RNA sequencing and genomic profiling, have facilitated novel approaches to risk assessment and prognostic evaluation in APTs. This review aims to provide a comprehensive overview of the diagnosis, clinical manifestations, and current molecular strategies used to assess the malignant potential of APTs.</p>","PeriodicalId":520607,"journal":{"name":"Endocrinology and metabolism (Seoul, Korea)","volume":" ","pages":"14-25"},"PeriodicalIF":4.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12963775/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145919634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}